一年两针!吉利德突破性长效HIV疗法获FDA批准上市

药渡
Yesterday

来源:药渡撰文:Pharmadeep编辑:维他命2025年6月18日,吉利德科学公司宣布,美国食品药品监督管理局(FDA)已批准其长效HIV-1衣壳抑制剂来那帕韦(lenacapavir,Yeztugo®)作为暴露前预防(PrEP)药物,用于降低成人和体重至少35公斤的青少年通过性途径感染HIV的风险。这是美国首个且唯一一款每年仅需注射两次的长效HIV预防方案,标志着HIV预防领域迈出了重大一步。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10